Introduction {#s1}
============

Depth of primary tumor invasion and nodal metastasis are considered as the most intensive factors for predicting the prognosis of gastric cancer (GC) patients after curative surgery. The tumor-node-metastasis (TNM) classification of the Union for International Cancer Control (UICC) for GC is considered as the best classification system because of its ability to provide precise prognostic estimation and guidance for patients through appropriate therapeutic programs. Moreover, the TNM classification can distinguish the prognostic differences among various subgroups of patients by providing the anatomical extent of the primary tumor, which is currently considered as the most important prognostic predictor of GC. The TNM classification for GC has been continuously revised for several decades to improve the accuracy of its prognostic prediction. Its seventh edition shows a more meticulous prognostic sub-stage than previous editions based on the elaborate redefinitions of depth of primary tumor invasion (T stage) and nodal metastasis (N stage) \[[@B1]\]. More changes have been done to the N stage than the T stage in the latest edition compared with the sixth edition of the TNM classification, thereby establishing a prognostic prediction classification that mainly relies on the reform of the stage of metastatic lymph node count for GC.

Many researchers agree that the metastatic lymph node count is more appropriate in evaluating the overall survival (OS) of GC patients who underwent curative resection than the ratio between metastatic and examined lymph nodes, which is regarded as the most intensive prognostic predictor of GC as validated by previous large-scale retrospective investigations \[[@B2]-[@B5]\]. Recently, we adopted the N stage of the seventh edition of the TNM classification for GC in evaluating the prognosis of patients after curative surgery. The results show that the N stage of the seventh edition was significantly superior to that of the sixth edition \[[@B6]\]. A surgeon from Korea also reported that the seventh edition of the TNM classification for lymph node metastasis was a more reliable prognostic factor for GC than the sixth edition \[[@B7]\]. Although few investigators reported that the seventh edition is not superior to the other clinicopathological variables in terms of predicting the prognosis of GC \[[@B8],[@B9]\], many are convinced that the seventh edition can provide a more stratified survival difference in the sub-stages of GC, which is considered to be much more reasonable compared with the sixth edition, especially between the N1- and N2-stage tumors \[[@B10]-[@B15]\].

Theoretically, we considered the seventh edition of the TNM classification for GC to be superior to any other clinicopathological variables. However, the tumor-ratio-metastasis (TrM) classification, which is based on the ratio between the metastatic and the examined lymph nodes, was reported to show obvious superiority to the seventh edition \[[@B16]\]. In addition, we previously demonstrated that the number of negative lymph nodes (NLNs) is significantly associated with the OS of GC patients after curative surgery \[[@B17]\]. Therefore, the aims of the present study are the following: 1) to elucidate if the seventh edition of the TNM classification is superior to the other clinicopathological variables in terms of evaluating the prognosis of GC; and 2) to identify if the prognostic prediction efficiency of the seventh edition of the TNM classification for GC can be improved by combining the number of negative nodes.

Methods {#s2}
=======

Patients {#s2.1}
--------

2326 patients with gastric cancer underwent surgical resection in the Department of Gastric Cancer Surgery, Tianjin Medical University Cancer Hospital between January 1997 and December 2006 were eligible for this study. Eligibility criteria for this study included: 1) histologically proven primary adenocarcinoma of the stomach, 2) no history of gastrectomy or other malignancy, 3) a lack of non-curative surgical factors except for distant metastasis (such as liver, lung, brain, or bone-marrow metastasis) and peritoneal dissemination, lymph node metastasis in para-aortic lymph node metastasis, 4) curative gastrectomy (subtotal or total) with lymphadenectomy performed (limited, or extended), 5) no gastroesophageal junction tumor or cardia tumor, 6) number of lymph nodes for pathological examination was no less than 15, 7) no patients died during the initial hospital stay or for 1 month after surgery.

As a result, 1557 patients were excluded from this study. Of these excluded patients, 147 had the history of gastrectomy, 92 had other malignancy, 113 presented with hepatic metastasis intra-operation, 83 had ovarian metastasis, 204 underwent palliative gastrectomy for para-aortic node metastasis, 145 had peritoneal dissemination, 47 died of serious complications, 415 had less than 15 examined lymph nodes, and 311 identified to be gastroesophageal junction cancer or cardia cancer. Ultimately, 769 patients were included in this study.

Surgical Treatment {#s2.2}
------------------

All patients were operated on according to the potentially curative gastrectomy plus lymphadenectomy method. Curative resection was deﬁned as a complete lack of grossly visible tumor tissue and metastatic lymph nodes remaining after resection, with pathologically negative resection margins \[[@B18]\]. Primary tumors were resected en bloc with limited or extended lymphadenectomy (D1 or D2-3 according to the Japanese Gastric Cancer Association (JGCA) \[[@B19]\]). Limited lymphadenectomy (D1) entails the removal of the perigastric nodes only, whereas extended lymphadenectomy (D2 or D3) involves the removal of both perigastric and extragastric nodes. The choice of surgical procedure of gastrectomy (total gastrectomy or subtotal gastrectomy) was made by the attending surgeon's preference, and based mainly on the gastric cancer treatment guidelines in Japan \[[@B20]\]. Surgical specimens were evaluated as recommended by the seventh edition of UICC TNM classification for gastric cancer.

Adjuvant Therapy {#s2.3}
----------------

135 patients (17.7%) received the adjuvant chemotherapy based on fluorouracil and leucovorin calcium after curative gastrectomy. Radiotherapy was not routinely administrated in patients routinely.

Ethics statement {#s2.4}
----------------

This study was approved by the Research Ethics Committee of Tianjin Medical University Cancer Institute and Hospital, and written informed consent was obtained from all patients.

Statistics {#s2.5}
----------

Categorical variables were statistically compared a χ^2^ or Fisher's exact test. Continuous data were shown as mean (s.d.) and were statistically compared using the Mann--Whitney test. To determine the most appropriate cut-off values for continuous data variables, the cut-point survival analysis \[[@B2],[@B21]\] was adopted. The median OS was determined by using the Kaplan-Meier method, and log-rank test was used to determine significance. Factors that were deemed of potential importance on univariate analyses (*P*\<0.05) were included in the multivariate analyses. Multivariate analysis of OS was performed by means of the Cox proportional hazards model. Hazard ratios (HR) and 95% CI were generated. The case-control matched logistic regression was used for demonstration the most intensively prognostic predictors. Linear trend χ^2^ test was used to evaluate the potential correlation among different variables. Measure of agree Kappa value and McNemar χ^2^ test were used to measure statistical consistency and homogeneity of various factors. To assess potential bias in comparing prognostic factors with different numbers of stages, the Akaike Information Criterion (AIC), and the Bayesian Information Criterion (BIC) were used. A smaller AIC or BIC value indicated a better model for predicting outcome \[[@B22],[@B23]\]. Significance was defined as *P* \< 0.05. All statistical analyses were performed with SPSS 18.0 software.

Follow-up {#s2.6}
---------

After curative surgery, all patients were followed every 3 or 6 months for 2 year at outpatient department, every year from the third to fifth years, and then annually thereafter until the patient died. The median follow-up for the entire cohort was 51 months (range: 2-141). The follow-up of all patients who were included in this study was completed in December 2011. Ultrasonography, CT scans, chest X-ray, and endoscopy were obtained with every visit.

Results {#s3}
=======

Clinicopathological Outcomes {#s3.1}
----------------------------

Data from 769 gastric cancer patients were analyzed. A total of 510 (66.3%) patients were male and 259 (33.7%) were female patients, with a median age of 57 years (range, 20-80 years). The median OS of all patients after curative surgery is 43.0 months, and the five year survival rates (5-YSR) is 43.8%. The patient and clinicopathological characteristics are shown in [Table 1](#pone-0080082-t001){ref-type="table"}. The tumor was located in the lower third stomach in 269 (35.0%) patients, in the middle third stomach in 275 (35.8%) patients, in upper third stomach in 153 (19.9%) patients, and in more than two thirds stomach in 72 (9.3%) patients. All patients underwent the curative gastrectomy with lymphadenectomy. 577 (75.0%) patients underwent the subtotal gastrectomy, and 192 (25.0%) patients underwent the total gastrectomy. The limited lymphadenectomy was performed in 267 (34.7%) patients, and the extended lymphadenectomy was performed in 502 (65.3%) patients. Of these 769 patients, 520 (67.6%) had lymph node metastasis and 634 (82.4%) had serosal invasion. A mean of 22.81±6.95 lymph nodes per patient was dissected for histopathological examination after surgery. The mean of number of NLNs per patient was 16.35±9.40, with a range form 0 to 61. According to the seventh edition of the TNM classification for gastric cancer, 42 (5.5%) patients were Ia stage, 40 (5.2%) patients were Ib stage, 36 (4.7%) patients were IIa stage, 139 (18.1%) patients were IIb stage, 123 (16.0%) patients were IIIa stage, 128 (16.6%) patients were IIIb stage, and 261 (33.9%) were IIIc stage. 446 (58.0%) patients died when the follow-up was over.

10.1371/journal.pone.0080082.t001

###### Clinicopathologic Characteristics of the Patients Cohort.

  ------------------------------------------------------------------------------------ -------------
  **Gender**                                                                           
  Male                                                                                 510 (66.3%)
  Female                                                                               259 (33.7%)
  **Age at surgery**                                                                   
  **Mean±SD**: 56.01 ± 11.68 years **Range**: 20 - 80 years                            
  \< 65                                                                                554 (72.0%)
  ≥ 65                                                                                 215 (28.0%)
  **Tumor location**                                                                   
  Lower third                                                                          269 (35.0%)
  Middle third                                                                         275 (35.8%)
  Upper third                                                                          153 (19.9%)
  More than 2/3                                                                        72 (9.3%)
  **Tumor size**                                                                       
  **Mean±SD**: 5.40 ± 2.79 cm **Range**: 0.3 - 19.0 cm                                 
  ≤ 3.5 cm                                                                             211 (27.4%)
  3.6-6.5 cm                                                                           337 (43.8%)
  \> 6.5 cm                                                                            221 (28.7%)
  **Depth of primary tumor invasion (T stage)[\*](#ngtab1.1){ref-type="table-fn"}**    
  T1                                                                                   45 (5.9%)
  T2                                                                                   42 (5.5%)
  T3                                                                                   48 (6.2%)
  T4a                                                                                  562 (73.1%)
  T4b                                                                                  72 (9.3%)
  **Extent of lymph node metastasis**                                                  
  No                                                                                   249 (32.4%)
  Perigastric                                                                          374 (48.6%)
  Extragastric                                                                         146 (19.0%)
  **Number of examined lymph nodes**                                                   
  **Mean±SD**: 22.81 ± 6.95 **Range**: 15 - 91                                         
  15-25                                                                                578 (75.2%)
  \> 25                                                                                191 (24.8%)
  **Number of metastatic lymph nodes (N stage)[\*](#ngtab1.1){ref-type="table-fn"}**   
  **Mean±SD**: 6.46 ± 5.07 **Range**: 0 - 91                                           
  N0                                                                                   249 (32.4%)
  N1                                                                                   120 (15.5%)
  N2                                                                                   134 (17.4%)
  N3a                                                                                  171 (22.2%)
  N3b                                                                                  95 (12.4%)
  **Number of negative lymph nodes (NLNs)**                                            
  **Mean±SD**: 16.35 ± 9.40 **Range**: 0 - 61                                          
  n1 (0-1)                                                                             23 (3.0%)
  n2 (2-9)                                                                             150 (19.5%)
  n3 (10-14)                                                                           137 (17.8%)
  n4 (15-36)                                                                           430 (55.9%)
  n5 (\>36)                                                                            29 (3.8%)
  **Ratio between metastatic and examined lymph nodes**                                
  **Mean±SD**: 27.21% ± 20.75% **Range**: 0% - 100%                                    
  r1 (≤ 5.00%)                                                                         283 (36.8%)
  r2 (5.01%-10.00%)                                                                    73 (9.5%)
  r3 (10.01%-40.00%)                                                                   181 (23.5%)
  r4 (40.01%-90.00%)                                                                   200 (26.0%)
  r5 (\> 90.00%)                                                                       32 (4.2%)
  **Type of gastrectomy**                                                              
  Subtotal                                                                             577 (75.0%)
  Total                                                                                192 (25.0%)
  **Extent of lymphadenectomy**                                                        
  Limited                                                                              267 (34.7%)
  Extended                                                                             502 (65.3%)
  **Lauren's classification of primary tumor**                                         
  Intestinal                                                                           310 (40.3%)
  Mixed                                                                                49 (6.4%)
  Diffuse                                                                              410 (53.3%)
  **TNM Classification[\*](#ngtab1.1){ref-type="table-fn"}**                           
  Ia                                                                                   42 (5.5%)
  Ib                                                                                   40 (5.2%)
  IIa                                                                                  36 (4.7%)
  IIb                                                                                  139 (18.1%)
  IIIa                                                                                 123 (16.0%)
  IIIb                                                                                 128 (16.6%)
  IIIc                                                                                 261 (33.9%)
  ------------------------------------------------------------------------------------ -------------

SD, standard deviation.

According to the seventh edition TNM Classification

Univariate and Multivariate Survival Analyses {#s3.2}
---------------------------------------------

With univariate analysis, thirteen clinicopathological variables were validated to have statistically significant associations with OS of 769 patients after curative surgery. There were age at surgery (*P* = 0.002), tumor location (*P* \< 0.001), tumor size (*P* \< 0.001), T stage (*P* \< 0.001), extent of lymph node metastasis (*P* \< 0.001), number of examined lymph nodes (*P* = 0.022), N stage (*P* \< 0.001), number of NLNs (*P* \< 0.001), ratio between metastatic and examined lymph nodes (*P* \< 0.001), type of gastrectomy (*P* \< 0.001), extent of lymphadenectomy (*P* = 0.003), Lauren's classification of primary tumor (*P* \< 0.001), and the seventh edition of TNM classification for gastric cancer (*P* \< 0.001).

All above thirteen variables were included in a multivariate Cox proportional hazards model (forward stepwise procedure) to adjust for the effects of covariates. With the multivariate Cox proportional hazards model (forward stepwise procedure) analysis, the seventh edition of TNM classification for GC (HR=1.797, *P* \< 0.001) was identified as the independent predictor with OS of GC patients, as were T stage (HR=1.115, *P* = 0.037), number of NLNs (HR=0.752, *P* \< 0.001), and type of gastrectomy (HR=1.563, *P* \< 0.001) ([Figure 1](#pone-0080082-g001){ref-type="fig"}).

![Survival curve for 769 gastric cancer patients after curative resection A) according to stage subgroup of TNM classification; B) according to stage subgroup of T stage; C) according to stage subgroup of number of negative lymph nodes; D) according to stage subgroup of type of gastrectomy.](pone.0080082.g001){#pone-0080082-g001}

Correlation Analysis between the Seventh Edition TNM Classification and Number of NLNs {#s3.3}
--------------------------------------------------------------------------------------

Among the independently prognostic predictors of gastric cancer, the number of NLNs was irrelevant to the seventh edition of TNM classification for gastric cancer. However, the number of NLNs was demonstrated to have significant association with the OS of gastric cancer patients after curative surgery in our previous study\[[@B17]\]. Theoretically speaking, the number of NLNs should be deemed as one of the most conventionally prognostic predictor of gastric cancer for enhancement the evaluation the accuracy of lymph node dissection which may be associated with the remnants of micro-metastasis in the lymph nodes \[[@B24]-[@B27]\]. We do believe the number of NLNs is a essentially prognostic predictor of gastric cancer which can reflect another important aspect of primary tumor progression. With the linear trend χ^2^ test, we demonstrated the seventh edition TNM classification was significantly associated with the number of NLNs (χ^2^ value = 577.877, *P* \< 0.001; likelihood ratio value = 645.455, *P* \< 0.001; linear--by--linear association value = 275.360, *P* \< 0.001; contingency coefficient value = 0.655, *P* \< 0.001). Generally, the 5-YSR increases in the special sub-stage of the seventh edition of TNM classification as the number of NLNs increase. Therefore, we considered the number of NLNs should be a key accessorial indicator for enhancement the seventh edition of TNM classification for prediction the prognosis of gastric cancer patients after curative surgery.

Various Prognostic Classifications Based on the Depth of Tumor Invasion and the Status of Nodal Metastasis {#s3.4}
----------------------------------------------------------------------------------------------------------

We redefined various prognostic variables based on the depth of tumor invasion and status of nodal metastasis to investigate further the exact prediction for prognosis of GC. These variables include TrM classification (representing the T stage--ratio between the metastatic and the examined nodes--metastasis classification), TnM classification (representing the T stage--NLNs--metastasis classification), and the TNnM classification (representing the T stage-N stage--number of NLNs--metastasis classification). We obtained the best stage of TrM classification to evaluate the OS of GC through the appropriate cut-off value analysis by using the Kaplan-Meier method. These stages include the following: 1) I stage (including T1r1-5M0, T2r1-5M0, and T3r1-3M0), 2) II stage (including T3r4-5M0 and T4r1-2M0), 3) III stage (T4r3M0), 4) IV stage (T4r4M0), and 5) V stage (T4r5M0). [Figure 2A](#pone-0080082-g002){ref-type="fig"} shows the patient distribution and stage-specific survival rates, and the Kaplan-Meier plot shows the optimal discriminatory ability among the sub-stages of the TrM classification. Similarly, we obtained the best stages of TnM classification for evaluating the OS of GC through the appropriate cut-off value analysis by using the Kaplan-Meier method. These stages include the following: 1) I stage (including T1n1-5M0, T2n1-5M0, T3n1-5M0, and T4n5M0), 2) II stage (T4n4M0), 3) III stage (T4n3M0), 4) IV stage (T4n2M0), and 5) V stage (T4n1M0). [Figure 2B](#pone-0080082-g002){ref-type="fig"} shows the patient distribution and the stage-specific survival rates, and the Kaplan-Meier plot shows the optimal discriminatory ability among the sub-stages of TrM classification. Finally, we obtained the best stages of the TNnM classification for evaluating the OS of GC by combining the seventh edition TNM classification and the number of NLNs. These stages include the following: 1) I stage (including T1-2N0-3n1-5M0, and T3N0n1-5M0), 2) II stage (T4N0n1-5M0), 3) III stage (T3N1n4-5M0, T4N1n4-5M0), 4) IV stage (including T3N1n1-3M0, T3N2-3n1-5M0, T4N1n1-3M0, and T4N2n1-5M0), 5) V stage (T4N3n2-5M0), and 6) VI stage (T4N3n1M0). [Figure 2C](#pone-0080082-g002){ref-type="fig"} shows the patient distribution and stage-specific survival rates, and the Kaplan-Meier plot shows the optimal discriminatory ability among the sub-stages of TrM classification.

![Survival curve for 769 gastric cancer patients after curative resection A) according to stage subgroup of TrM classification; B) according to stage subgroup of TnM classification; C) according to stage subgroup of TNnM classification.](pone.0080082.g002){#pone-0080082-g002}

Analyses of the Most Appropriately Prognostic Classification for Prediction the OS of Gastric Cancer Patients {#s3.5}
-------------------------------------------------------------------------------------------------------------

To obtain the most appropriately prognostic classification for prediction the OS of gastric cancer patients in solid statistical method, we adopted the case-control matched logistic regression (using the forward stepwise procedure) to directly compare the different prognostic classification taking into both depth of primary tumor invasion and status of nodal metastasis. In this matched fashion, we matched 303 couple of patients (the ratio between the number of cases and the number of controls = 1:1) in accordance with variables of the type of gastrectomy (subtotal VS total), the number of examined lymph nodes (15-25 VS \>25), and the extent of lymphadenectomy (limited VS extended). With the case-control matched analysis, we found the TNnM classification (HR=1.682, *P* \< 0.001) was the most appropriately prognostic classification for prediction the OS of gastric cancer patients after curative surgery, rather than the seventh edition of TNM classification (*P* = 0.172), the TrM classification (*P* = 0.308), or the TnM classification (*P* = 0.001).

Exploring the Superiorities of TNnM Classification to the Seventh Edition TNM Classification in Predicting the OS of GC Patients {#s3.6}
--------------------------------------------------------------------------------------------------------------------------------

The seventh edition TNM classification for GC has been generally recognized and applied worldwide since 2009. In this study, the Kaplan-Meier plot shows the optimal discriminatory ability among the sub-stages of TNM classification except Ia and Ib (*P*=0.928). On the other hand, we also determined that the discriminatory ability among the sub-stages of TNnM classification is comprehensively distinguished. The differences in prognostic prediction between the seventh edition of the TNM classification and the TNnM classification were directly compared for convenience. We changed the sub-stages of the seventh edition TNM classification by combining Ia and Ib ([Figure 3](#pone-0080082-g003){ref-type="fig"}). Subsequently, both TNM and TNnM classifications had six sub-stages for further statistical analysis. [Table 2](#pone-0080082-t002){ref-type="table"} shows the patient distribution and stage-specific survival rates for different classifications. With a symmetric measure of agreement, the value of Kappa between the TNM and TNnM classifications was only 0.018, which indicates a negative statistical consistency for prognostic prediction of GC patients. In addition, McNemar χ^2^ test results show no homogeneity was observed in the prognostic prediction between the TNM and TNnM classifications (*P*\<0.001).

![Survival curve for 769 gastric cancer patients after curative resection according to stage subgroup of TNM classification revision.](pone.0080082.g003){#pone-0080082-g003}

10.1371/journal.pone.0080082.t002

###### Distribution and stage specific survival rates of different classifications for prediction the prognosis of GC patients.

  **Variables**                            **5-YSR (%**)   **Number of patients**
  ---------------------------------------- --------------- ------------------------
  **The 7th edition TNM classification**                   
  Ia                                       97.6            42
  Ib                                       95.0            40
  (Ia-Ib)                                  (96.3)          \(82\)
  IIa                                      91.7            36
  IIb                                      70.9            139
  IIIa                                     57.4            123
  IIIb                                     30.4            128
  IIIc                                     5.1             261
  **TNnM classification**                                  
  I                                        95.0            121
  II                                       71.2            134
  III                                      54.1            106
  IV                                       35.3            147
  V                                        5.5             238
  VI                                       0               23

Ultimately, we adopted the generalized multinomial logistic regression model to calculate the values of AIC and BIC to demonstrate that the TNnM classification was superior to the TNM classification in predicating the prognosis of GC patients after curative surgery. With this model, we adopted all the clinicopathological variables relative to the OS of the GC patients (TrM classification, TnM classification, and TNnM classification) as the covariates. The survival status of the patients is defined as the dependent factor in demonstrating the differences in prognostic evaluation of various variables. Based on the results, we identified that the TNnM classification had the smallest AIC and BIC values among all the covariates (AIC value=594.001 and BIC value=663.677) instead of the seventh edition of the TNM classification (AIC value=595.963 and BIC value=670.285) ([Table 3](#pone-0080082-t003){ref-type="table"}).

10.1371/journal.pone.0080082.t003

###### AIC and BIC values of various clinicopathological variables.

  **Variables**                                            **AIC value**   **BIC value**
  -------------------------------------------------------- --------------- ---------------
  Age at surgery                                           595.735         665.412
  Tumor location                                           596.834         666.510
  Tumor size                                               595.943         665.619
  T stage[\*](#ngtab3.1){ref-type="table-fn"}              595.963         670.285
  Extent of lymph node metastasis                          594.230         663.906
  Number of examined lymph nodes                           594.486         664.162
  N stage[\*](#ngtab3.1){ref-type="table-fn"}              595.963         670.285
  Number of NLNs                                           604.557         674.233
  Ratio between metastatic and examined lymph nodes        594.270         663.947
  Type of gastrectomy                                      600.068         669.744
  Extent of lymphadenectomy                                594.141         663.818
  Lauren's classification of primary tumor                 597.383         667.060
  TNM classification[\*](#ngtab3.1){ref-type="table-fn"}   595.963         670.285
  TrM classification                                       597.964         667.641
  TnM classification                                       598.120         667.796
  **TNnM classification**                                  **594.001**     **663.677**

According to the seventh edition TNM Classification

Discussion {#s4}
==========

Lymph node involvement is considered as the most important prognostic indicator of GC after curative resection regardless of the progress of primary tumor. Hitherto, most clinical investigators were in consensus that the efficiency of the number of lymph node metastasis in predicating the prognosis of GC is far better than that of the location of lymph node metastasis \[[@B28]-[@B30]\]. Thus, many retrospective studies have identified that the ratio between the metastatic and the examined lymph nodes was superior to the number of lymph node metastasis in terms of predicating the prognosis of GC as evidenced by the avoidance of the stage migration of malignant disease \[[@B4],[@B31]\]. Recent studies have failed to demonstrate the superiority of the ratio between the metastatic and the examined lymph nodes in evaluating the prognosis of GC compared with the number of lymph node metastasis \[[@B2],[@B3]\]. In theory, the ratio between the metastatic and the examined lymph nodes cannot provide complete information on both the location and the number of positive nodes of patients who had a few intraoperatively dissected lymph nodes \[[@B32]\]. In our previous investigation, we successfully demonstrated that the revised category of metastatic lymph node count significantly exceeded the efficiency of the ratio between the metastatic and the examined lymph nodes compared with the N stage of the sixth edition TNM classification for GC in predicating the OS of patients who had at least 15 dissected nodes by using a solid statistical method (case-control matched fashion) \[[@B31]\]. N stage reclassification is the major revision in the seventh edition of the TNM classification for GC, which was identified to be perfectly suitable for predicating the prognosis of GC \[[@B6],[@B12],[@B13]\]. Several supplements to the N stage were proposed to enhance the efficiency of the seventh edition TNM classification for GC in predicating the prognosis of GC patients \[[@B12],[@B33],[@B34]\]. The most optimal category for evaluating the prognosis of patients with nodal metastasis of GC still remains controversial.

NLN count has recently been given importance for its significant association with the prognosis of patients with malignant disease \[[@B17],[@B25],[@B35]-[@B37]\]. In theory, an increasing number of examined NLNs indicates a comparatively good survival chance of patients with malignant disease after surgery with the aide of authoritative surgical curability and a sound host immune response \[[@B17],[@B26],[@B35]\]. Researchers have reported that a small proportion of GC patients with negative node metastasis examined by the conventional histological hematoxylin-eosin (HE) staining could not prevent the recurrence of GC, even after extended lymphadenectomy \[[@B38]-[@B41]\]. The isolated tumor cells and micrometastasis in negative lymph nodes are considered as the key factors that could lead to the adverse effect on the OS of GC patients \[[@B42]-[@B44]\]. Simultaneously, patients with NLN metastasis who were identified to have isolated tumor cells did not demonstrate a significantly worse prognosis than those who did not have isolated tumor cells after curative gastrectomy with extended lymphadenectomy \[[@B45]\]. Harrison et al \[[@B46]\] demonstrated that T3N0M0 GC patients who underwent extended lymphadenectomy had significantly more negative lymph nodes than those who underwent limited lymphadenectomy, thereby indicating that extended lymphadenectomy can improve the OS of T3N0M0 patients. This result is potentially associated with the elimination of micrommetastasis in NLNs. In our pervious study, we demonstrated that extended lymphadenectomy can improve the OS of GC patients with only perigastric nodal metastasis \[[@B47]\]. In that study, we have identified that the most important independent factor for improving the OS of GC patients with perigastric nodal metastasis after extended lymphadenectomy was the number of negative lymph nodes. In the present study, the number of NLNs was also an independent predictor of the OS of GC patients. More importantly, a significantly negative association was observed between the sub-stage of the seventh edition TNM classification and the sub-stage of the number of NLNs through the linear trend χ^2^ test. Therefore, we considered that the number of negative lymph nodes should be regarded as an indispensable predictor of the prognosis of GC after surgery, in addition to the seventh edition of TNM classification, T stage, and type of gastrectomy. Among the independent prognostic factors for GC patients after curative surgery, the T stage should be regarded as the essential part of the seventh edition of TNM classification for GC. Gastrectomy type, which is another independent prognostic factor, is a potentially subjective decision of the surgeon based on the clinical characteristics of the primary tumor in the operation. Therefore, combining the number of NLNs with the seventh edition of the TNM classification is necessary to explore the meticulous survival differences among the subgroups of GC patients after curative surgery.

Subsequently, we designed various versions that combine the number of NLNs and the seventh edition of the TNM classification to validate the optimal classification for identifying the prognostic differences of the subgroups of GC patients after curative surgery. The TRM classification was significantly superior to the TNM classification in predicating the OS of GC more accurately; therefore, it can be used as an alternative to the TNM system \[[@B16],[@B48]\]. We also considered that the ratio between the metastatic and the examined lymph nodes (including the number of NLNs) can acquire more comprehensive information such as lymph node metastasis from GC, potential micrometastasis, and host immune response than the number of metastatic lymph nodes (T stage). Unlike the TrM classification, the TNnM classification directly comprise information on both the number of metastatic nodes and the number of negative lymph nodes; thus, it can elaborately discriminate the survival differences in the subgroups of patients in the special T stage stratified by the number of negative lymph nodes. With the case-control matched test, the TNnM classification is identified as the most appropriate survival-predicating classification for GC patients after curative surgery. In this solid method analysis, we matched the type of gastrectomy to separate the surgeons' potentially objective intervention to the bias of survival analysis. We also matched the extent of lymphadenectomy and the number of examined lymph nodes to remove the objective bias of surgeons and pathologists to the survival analysis. The results of the case-control matched test show that the TNnM classification (*P*\<0.001) was the most appropriate prognostic classification for predicating the OS of GC patients after curative surgery, followed by the TnM classification (*P*=0.001). In addition, the seventh edition of the TNM classification and the TRM classification were not identified as appropriate predictors of the OS of the patients.

We adopted the consistency χ^2^ test in exploring the symmetric level between the TNnM classification and the seventh edition of TNM classification to deduce the superiority of the TNnM classification in evaluating the postoperative prognosis of GC patients after curative surgery. Unfortunately, the Kappa value of agreement was only 0.018, which implies that the survival prediction difference of GC patients was very significant between the seventh edition TNM classification and the TNnM classification. Furthermore, the McNemar χ^2^ test results show that no homogeneity was observed in prognostic prediction between the TNM and TNnM classification. Based on the results of [Figure 1A, Figure 2C, and Table 2](#pone-0080082-g001){ref-type="fig"}, no overlapping survival curves or 5-YSR was observed among all the sub-stages of the TNnM classification, whereas several obviously overlapping survival curves and 5-YRS were observed among all the sub-stages of the seventh edition of the TNM classification. The most significant prognostic prediction difference between the seventh edition TNM classification and the TNnM classification for GC are as follows: 1) the survival curves of the seventh edition of the TNM classification show that no survival difference was observed among the subgroups of GC patients in Ia (97.6% of 5-YSR), Ib (95.0% of 5-YSR), and IIa (91.7% of 5-YSR) stages. Within the TNnM classification survival curves, the 5-YSR of all the patients in the I stage, 118 patients in the Ia, Ib, IIa stages, and three patients in the IIb and IIIa stages reached 95.0%. This result indicates that patients with or without subserosal invasion, with or without lymph node metastasis, can achieve optimal prognosis after curative surgery. 2) Although the number of NLNs did not demonstrate significant associations with the OS in the subgroups of the T3N0M0, T3N2M0, and T3N3M0 patients, the T3N1n4-5M0 patients had much higher 5-YSR than the T3N1n1-3M0 patients. 3) For the patients with serosal invasion, the 5-YSR decreased with increased number of metastatic lymph nodes. Moreover, a significant survival difference was observed between the T4N1n1-3M0 patients and the T4N1n4-5M0 patients. A similar phenomenon was observed in the subgroups of T4N3M0 patients with various negative lymph node counts. 4) GC patients with the worst prognosis in this study were identified in the IIIc stage in the seventh edition of the TNM classification with a 5-YSR of 5.1%, which is divided into V (238 patients with 5.5% 5-YSR) and VI (23 patients with 0% 5-YSR) stages in the TNnM classification. Among these patients, the number of NLNs was a key criterion for distinguishing the survival differences among the subgroups of patients after curative surgery (shown in [Table 2](#pone-0080082-t002){ref-type="table"}). Therefore, we conclude based on the aforementioned results that the number of NLNs should not be ignored when predicating the prognosis of GC patients with more than T3N0M0 sub-stage based on the seventh edition of the TNM classification.

In conclusion, NLN count should be utilized to enhance the seventh edition of the TNM classification in evaluating the prognosis of GC after curative surgery. Admittedly, our present study is limited by the fact that it is retrospective in design and does not involve a large number of patients. However, we have initially explored and clarified that the number of NLN count is a promising indicator to be utilized when evaluating the prognosis of GC after curative surgery.
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